David McCoy, MD
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,298 of the $5,506 with a category attached, or 78.1%. 27 manufacturers reported payments, led by Medtronic at 35.2% of the total. Reporting peaked in 2019 at $3,110 and has fallen 89.1% since, to $338 in 2025.
Across 225 payments — averaging $24.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Abbott$912
- Teva Pharmaceuticals USA, Inc.$619
- Sunovion Pharmaceuticals Inc.$258
- Lundbeck LLC$231
- TG Therapeutics, Inc.$225
- plus $1K from 21 others
What the payments were for
- Speaking & faculty fees$270%
- Travel & lodging$85816%
- Food & beverage$4,29878%
- Education$3236%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 24 | $1,936 |
| Abbott | 24 | $912 |
| Teva Pharmaceuticals USA, Inc. | 42 | $619 |
| Sunovion Pharmaceuticals Inc. | 28 | $258 |
| Lundbeck LLC | 11 | $231 |
| TG Therapeutics, Inc. | 4 | $225 |
| SK Life Science, Inc. | 8 | $211 |
| AbbVie(2 entities) | 11 | $175 |
| UCB, Inc. | 17 | $174 |
| AstraZeneca | 7 | $122 |
| Livanova USA, Inc. | 4 | $89 |
| Sumitomo Pharma America, Inc. | 15 | $88 |
| Amgen | 5 | $86 |
| Novartis | 5 | $69 |
| Amneal Pharmaceuticals LLC | 4 | $59 |
| Eisai Inc. | 2 | $46 |
| Lilly USA, LLC | 3 | $45 |
| Acorda Therapeutics, Inc | 2 | $27 |
| Argenx US, Inc. | 1 | $21 |
| Sanofi | 1 | $19 |
| Neuronetics, Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $12 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
| Biogen | 1 | $11 |
| Vertical Pharmaceuticals, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYNCHROMED$999
- ACTIVA$391
- BRIUMVI$150
- NORTHERA$127
- INFINITY$124
- Cenobamate$119
How this compares
$5,506 in reported general payments places this provider in the 65th percentile of 152 neurology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 30 | $458,847 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 17 | $253,874 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 16 | $110,279 |
| CopaxoneGlatiramer Acetate | 14 | $80,337 |
| Droxidopa | 14 | $56,548 |
| Nurtec OdtRimegepant Sulfate | 19 | $35,793 |
| Aimovig AutoinjectorErenumab-Aooe | 31 | $30,728 |
| XcopriCenobamate | 22 | $27,141 |
| BriviactBrivaracetam | 12 | $16,021 |
| RytaryCarbidopa/Levodopa | 12 | $13,423 |
| Rasagiline Mesylate | 84 | $12,201 |
| BrilintaTicagrelor | 16 | $11,305 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 397 | $9,285 |
| Lacosamide | 80 | $8,983 |
| BotoxOnabotulinumtoxina | 11 | $8,536 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Copaxone | $619 | $539,18444 claims |
| SK Life Science, Inc.Xcopri | $211 | $27,14122 claims |
| UCB, Inc.Briviact | $174 | $16,02112 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $59 | $15,88842 claims |
| AstraZenecaBrilinta | $122 | $11,30516 claims |
| AbbVieBotox | $175 | $8,53611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 152 neurology providers in Oklahoma.
Other neurology in Yukon
- Cherian KarunapuzhaOklahoma City$4.1M
- Gabriel PardoOklahoma City$1.5M
- Jaclyn DuvallTulsa$1.4M
- Gregory ConnorTulsa$444K
- Brett DeesNorman$420K
- Eduardo de SousaMoore$393K
- Tania ReynaTulsa$353K
- Marguerite ButcheeOklahoma City$324K
- Chelsea BerkleyOklahoma City$277K
- Baha Abu-EshehArdmore$230K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.